CTLA4 and melanoma: Additionally, STING pathway activation was necessary to the synergy between 50 μCi 90Y-NM600 and anti-CTLA4 in B16 melanoma, highlighting the essential role of this pathway in certain combination TRT and immunotherapy regimens [53].